Imugene Progresses VAXINIA trial in December quarter
- Imugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer patients
- During the three months to December 31, 2022 the company saw its first patient dosed in VAXINIA intravenous (IV) cohort two
- The company also added to its management team during the quarter, with the appointments of Dr Giovanni Selvaggi and Paul Wright
- The company says it’s well funded to continue its clinical pipeline and operations, with cash at bank sitting at $161.9 million
- IMU shares were down 3.33 per cent, trading at 14.5 cents at 3:45 pm AEDT
